首页 | 本学科首页   官方微博 | 高级检索  
检索        

黄连素对新诊断2型糖尿病患者非酒精性脂肪肝及血液流变学的影响
引用本文:谢小铭,孟晓军,周小军,舒晓春,孔红娟.黄连素对新诊断2型糖尿病患者非酒精性脂肪肝及血液流变学的影响[J].中国中药杂志,2011,36(21):3032-3035.
作者姓名:谢小铭  孟晓军  周小军  舒晓春  孔红娟
作者单位:中山大学附属第五医院,广东珠海,519000
摘    要:目的:探讨黄连素对诊断2型糖尿病(T2DM)伴非酒精性脂肪肝及血流变的治疗效果.方法:选取2009年3月至2010年3月就诊的60例新诊断T2DM伴非酒精性脂肪肝患者,随机分为2组,分别给予黄连素及血脂康治疗,疗程12周.检测2组患者治疗前后肝脏B超、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、丙氨酸氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)、血流变等指标并进行比较.结果:黄连素组治疗后复查肝脏B超显效及有效共21例,有效率70.0%,血脂康组有效共22例,有效率73.3%,2组疗效无差异.黄连素组治疗后ALT,AST,TC,TG,LDL-L,血流变(包括全血粘度、全血高切还原粘度、全血低切还原粘度、血浆粘度、血沉、红细胞压积、纤维蛋白原)水平均较治疗前明显降低,HDL-L水平明显升高(P<0.05);血脂康组亦显示出相同的结果(P<0.05);2组各指标治疗前后的差值均无明显差异.结论:黄连素能明显改善新诊断T2DM伴非酒精性脂肪肝患者肝脏病变,有效降低血流变相关指标,具有良好的应用前景.

关 键 词:黄连素  2型糖尿病  非酒精性脂肪肝  血液流变学
收稿时间:4/8/2011 12:00:00 AM

Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease
XIE Xiaoming,MENG Xiaojun,ZHOU Xiaojun,SHU Xiaochun and KONG Hongjuan.Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease[J].China Journal of Chinese Materia Medica,2011,36(21):3032-3035.
Authors:XIE Xiaoming  MENG Xiaojun  ZHOU Xiaojun  SHU Xiaochun and KONG Hongjuan
Institution:No. 5 Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, China;No. 5 Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, China;No. 5 Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, China;No. 5 Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, China;No. 5 Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, China
Abstract:Objective: To explore the therapeutic effect and the hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease. Method: Sixty patients, in our department from March 2009 to March 2010, with type 2 diabetes and nonalcoholic fatty liver disease were randomly divided into two groups. One group was given berberine, another group was given Xuezhikang, both for 12 weeks. The indicators, include B-ultrasound of liver, triglycerides (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), alanine aminotransferase (ALT), aspertate aminotransferase (AST), hemorrheology, were detected before and after treatment. Result: After treatment by berberine, B-ultrasound of liver were better than before, the effective rate was 70%, vs 73.3% after treatment by Xuezhikang. ALT,AST,TC,TG,LDL-L,hemorrheology (including the whole blood viscosity, whole blood viscosity, high cutting reduction of whole blood viscosity, plasma cutting reductive low viscosity, blood sedimentation, RBC deposited, fibrinogen) were significantly lower than before, however, HDL-L significantly increased (P<0.05). The therapeutic effect of xuezhikang was the same as berberine. The distance between the indicators of the two groups was no different. Conclusion: Berberine can obviously improve the conditions of new diagnostic T2DM patients with nonalcoholic liver lesions, effectively reduce hemorrheology indicators, and has good application prospect.
Keywords:berberine  type 2 diabetes  nonalcoholic fatty liver disease  hemorheology
本文献已被 CNKI 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号